$OFRM

Once Upon a Farm (OFRM) presented at the Barclays Global Consumer Conference, reporting revenue growth from less than $1M in 2017 to over $300M this year. The company aims to become a billion-dollar brand, with household penetration at 6.2% and repeat rates above 50%. Management highlighted a cooler strategy, targeting 5,000 coolers by year-end, and long-term margin goals of 45% gross and mid-to-upper teens EBITDA.

Once Upon A Farm (OFRM) reported Q2 FY2026 net sales of $85.4 million, up 42.3% year over year on a 40.3% volume increase. Management raised full-year net sales guidance to $327 million to $335 million and adjusted EBITDA to $3.0 million to $4.5 million. Gross margin was 35.9% and the company had a $5.0 million net loss.

Once Upon a Farm (NYSE:OFRM) reported Q2 growth, with baby sales up 73% to $41.5M and kid sales up 22% to $43.9M, alongside distribution point expansion. Gross margin fell to 35.9% (down 485 bps). SG&A rose to $36.3M. Net loss was $5M. The company cut FY gross margin outlook to ~40% and expects Q3 similar margins.

Once Upon a Farm (NYSE: OFRM) reported Q2 2026 net sales up more than 42% year over year to $85.4 million, beating expectations, and raised full-year revenue guidance for a second straight quarter. The company now forecasts 2026 net sales of $325 million to $335 million, citing continued distribution expansion and growth in baby and kids categories.

Once Upon a Farm, PBC (OFRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Once Upon a Farm Reports Second Quarter 2026 Financial Results Second quarter net sales increased 42% year-over-year to $85 million Raising 2026 net sales outlook to $327 million to $335 million Raising 2026 Adjusted EBITDA outlook to $3 million to $4.5 million BERKELEY, Calif.,

Once Upon a Farm has launched a significant expansion of its product portfolio, introducing new nutrient-dense pouches for children. These new offerings include options like Meat, Meat & Bone Broth, Legume Blends, and Smoothies with Protein & Probiotics, catering to different developmental stages from infants to active kids. The expansion aims to meet parental demand for convenient, organic, and farm-fresh nutrition, moving into refrigerated protein-forward formats.

Stifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.